Myeloma: First-in-Class ADC Regimen Yields Key Benefits ...Middle East

Medscape - News
The DREAMM-8 trial showed that adding belantamab mafodotin to pomalidomide and dexamethasone significantly improved progression-free survival in patients with relapsed or refractory multiple myeloma. Medscape Medical News

Hence then, the article about myeloma first in class adc regimen yields key benefits was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Myeloma: First-in-Class ADC Regimen Yields Key Benefits )

Apple Storegoogle play

Last updated :

Also on site :